BEAT AML

The Leukemia & Lymphoma Society (LLS) has more good news to share about acute myeloid leukemia (AML)! Celator Pharmaceuticals, an important biotechnology partner in LLS’s Therapy Acceleration Program, released data this week regarding its study of an experimental therapy – a special formulation of two standard chemotherapy drugs to treat elderly patients with high-risk AML. The new therapy performed better than the standard course of treatment currently used. With a patient response rate of more than 47%, this news is very encouraging as it represents a positive advance for patients with few options for effective treatment. We’ve been telling you that AML is an aggressive blood cancer with a survival rate of just more than 25% across all cases and how treatment hasn’t changed for more than 30 years. We believe this is about to change. We set a goal of $300,000 by June 30 to support our Beat AML collaboration with Oregon Health & Science University, and, thanks to supporters like you, we reached it with a few days to spare. But like LLS researchers, we won’t stop there. Please join us in surpassing our goal, because it’s time for a cure. Thank you, Michael C. Copley National Chairman LLS's Beat AML Campaign

If you need help or to learn more about specific blood cancers: www.lls.org/diseaseinformation/ National Office 1311 Mamaroneck Avenue  |  White Plains, NY 10605  |  888.557.7177  |  www.LLS.org © 2015 The Leukemia & Lymphoma Society  |  All Rights Reserved This email was sent to: jcassidy@seniorplanningadvisors.com If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or click on the following link: Unsubscribe To ensure future delivery of emails, please add newsletter@email.lls.org to your safe sender list or address book. About LLS: www.LLS.org | Facebook | Twitter | YouTube | Google+ | Disclaimer | Public Disclosure